Physical activity for people with lung cancer

2020 ◽  
Vol 49 (4) ◽  
pp. 175-181
Author(s):  
Lara Edbrooke ◽  
Catherine L Granger ◽  
Linda Denehy
BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Brett C. Bade ◽  
Geliang Gan ◽  
Fangyong Li ◽  
Lingeng Lu ◽  
Lynn Tanoue ◽  
...  

Abstract Background Lung cancer survivors need more options to improve quality of life (QoL). It is unclear to what extent patients with advanced stage disease are willing to participate in home-based physical activity (PA) and if these interventions improve QoL. The goal of our study was to determine interest in participating in our 3-month home-based walking regimen in patients with advanced stage lung cancer. We used a randomized design to evaluate for potential benefit in PA and patient-reported outcomes. Methods We performed an open-label, 1:1 randomized trial in 40 patients with stage III/IV non-small cell lung cancer (NSCLC) evaluating enrollment rate, PA, QoL, dyspnea, depression, and biomarkers. Compared to usual care (UC), the intervention group (IG) received an accelerometer, in-person teaching session, and gain-framed text messages for 12 weeks. Results We enrolled 56% (40/71) of eligible patients. Participants were on average 65 years and enrolled 1.9 years from diagnosis. Most patients were women (75%), and receiving treatment (85%) for stage IV (73%) adenocarcinoma (83%). A minority of patients were employed part-time or full time (38%). Both groups reported low baseline PA (IG mean 37 (Standard deviation (SD) 46) vs UC 59 (SD 56) minutes/week; p = 0.25). The IG increased PA more than UC (mean change IG + 123 (SD 212) vs UC + 35 (SD 103) minutes/week; p = 0.051)). Step count in the IG was not statistically different between baseline (4707 step/day), week 6 (5605; p = 0.16), and week 12 (4606 steps/day; p = 0.87). The intervention improved EORTC role functioning domain (17 points; p = 0.022) with borderline improvement in dyspnea (− 13 points; p = 0.051) compared to UC. In patients with two blood samples (25%), we observed a significant increase in soluble PD-1 (219.8 (SD 54.5) pg/mL; p < 0.001). Conclusions Our pilot trial using a 3-month, home-based, mobile health intervention enrolled over half of eligible patients with stage III and IV NSCLC. The intervention increased PA, and may improve several aspects of QoL. We also identified potential biomarker changes relevant to lung cancer biology. Future research should use a larger sample to examine the effect of exercise on cancer biomarkers, which may mediate the association between PA and QoL. Clinical trial registration Clinicaltrials.gov (NCT03352245).


2016 ◽  
Vol 26 (3) ◽  
pp. 173-181 ◽  
Author(s):  
Shanliang Zhong ◽  
Tengfei Ma ◽  
Lin Chen ◽  
Weixian Chen ◽  
Mengmeng Lv ◽  
...  

2013 ◽  
Vol 22 (2) ◽  
pp. 495-502 ◽  
Author(s):  
Errol J. Philip ◽  
Elliot J. Coups ◽  
Marc B. Feinstein ◽  
Bernard J. Park ◽  
Donna J. Wilson ◽  
...  

1999 ◽  
Vol 28 (4) ◽  
pp. 620-625 ◽  
Author(s):  
I. M. Lee ◽  
H. D. Sesso ◽  
R. S. Paffenbarger

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Joseph W. Turban

Spontaneous pneumomediastinum (SPM) is a fairly rare condition, caused by increased intrathoracic pressure, leading to free air in the mediastinal structures. Underlying lung conditions are associated with increased incidence of SPM, including asthma, interstitial lung disease, pneumonia, bullous lung, and radiation therapy for lung cancer. It is often preceded by Valsalva maneuvers, vomiting, coughing, asthma exacerbation, sneezing, childbirth, or intense physical activity. A case of SPM is presented in a 15-year-old male, who complained of throat pain and dyspnea while running sprints at football practice. Workup revealed SPM, and he was subsequently admitted and treated conservatively. His symptoms resolved in 2 days and he was discharged and suffered no further recurrences. In contrast to secondary pneumomediastinum, SPM is usually a benign condition although life-threatening conditions can rarely arise. Differentiating between these two conditions has important prognostic indications. There is a paucity of prospectively collected data regarding SPM, and considerable variation in recommendations concerning the extent of workup.


Lung Cancer ◽  
2013 ◽  
Vol 82 (3) ◽  
pp. 383-389 ◽  
Author(s):  
Edith Filaire ◽  
Carmen Dupuis ◽  
Géraud Galvaing ◽  
Sylvie Aubreton ◽  
Hélène Laurent ◽  
...  

2018 ◽  
Vol 28 (1) ◽  
pp. e12946 ◽  
Author(s):  
Catherine L. Granger ◽  
Selina M. Parry ◽  
Lara Edbrooke ◽  
Shaza Abo ◽  
Nina Leggett ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document